指南与共识肝病

囊性纤维化肝胆疾病筛查、评估与管理共识建议

Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.
指南 / 共识 · Hepatology · 2023-10-26

囊性纤维化基金会组建多学科委员会,基于31个PICO问题系统检索文献(初筛6401篇,全文评阅1053篇),经80%同意阈值投票产生筛查、监测与治疗建议,并公开征求意见后形成肝胆疾病管理共识。

要点

  • 共识涵盖囊性纤维化肝胆疾病筛查、现有疾病监测及治疗三方面推荐。
  • 委员会由肝病、消化、呼吸、药学、护理、营养专家及患者家庭组成。
  • 推荐经80%同意阈值投票通过,肝活检相关建议未达阈值。

核心结论

  • 通过多学科委员会与公众参与,形成了囊性纤维化相关肝胆受累及晚期肝病筛查、监测和治疗的更新推荐与指导。
  • 原文指出研究空白仍存在,并预期这些推荐将通过更早发现和更多循证监测治疗方式改善囊性纤维化结局。

研究设计与样本

  • 囊性纤维化基金会组建委员会,成员包括肝病学家、胃肠病学家、呼吸病学家、药师、护士、营养师、囊性纤维化患者及患儿父母。
  • 针对囊性纤维化肝胆疾病构建31个「人群、干预、比较和结局」问题,每个问题行PubMed文献检索。
  • 共初筛6401篇文稿的相关性,1053篇文稿接受详细全文评阅。
  • 推荐以80%同意为批准阈值投票,最终推荐形成前公开征求对初始推荐的意见。

主要发现

  • 共组装31个「人群、干预、比较和结局」问题,初筛6401篇文稿,1053篇接受全文评阅。
  • 筛查方面7条推荐获批,现有疾病监测方面13条获批,囊性纤维化相关肝胆受累或晚期肝病治疗方面14条获批。
  • 关于肝活检的1条推荐未达到80%阈值。
  • 关于筛查超声的1条推荐经修订后重新投票。

关键数值与推荐

  • 筛查推荐7条获批。
  • 现有疾病监测推荐13条获批。
  • 囊性纤维化相关肝胆受累或晚期肝病治疗推荐14条获批。
  • 推荐批准阈值为80%同意。
  • 肝活检推荐1条未达80%阈值。

局限性

  • 原文指出研究空白仍存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cystic fibrosis (CF) may cause a spectrum of hepatobiliary complications, including portal hypertension, multilobular cirrhosis, and liver failure. Current guidelines on the detection and monitoring of hepatobiliary complications in CF were published in 1999. The CF Foundation assembled a committee to evaluate research advances and formulate revised guidelines for CF-associated liver disease. A committee of hepatologists, gastroenterologists, pulmonologists, pharmacists, nurses, dietitians, individuals with CF, and the parents of a child with CF devised "population, intervention, comparison, and outcome" questions regarding hepatobiliary disease in CF. PubMed literature searches were performed for each population, intervention, comparison, and outcome question. Recommendations were voted on with 80% agreement required to approve a recommendation. Public comment on initial recommendations was solicited prior to the formulation of final recommendations. Thirty-one population, intervention, comparison, and outcome questions were assembled, 6401 manuscripts were title screened for relevance, with 1053 manuscripts undergoing detailed full-text review. Seven recommendations were approved for screening, 13 for monitoring of existing disease, and 14 for treatment of CF-associated hepatobiliary involvement or advanced liver disease. One recommendation on liver biopsy did not meet the 80% threshold. One recommendation on screening ultrasound was revised and re-voted on. Through a multidisciplinary committee and public engagement, we have assembled updated recommendations and guidance on screening, monitoring, and treatment of CF-associated hepatobiliary involvement and advanced liver disease. While research gaps remain, we anticipate that these recommendations will lead to improvements in CF outcomes through earlier detection and increased evidence-based approaches to monitoring and treatment.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sellers ZM, Assis DN, Paranjape SM, et al. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology. 2023. PMID: 37934656. doi:10.1097/HEP.0000000000000646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。